| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US10532047 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10414752 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US11498913 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US10550098 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US10959994 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
| US11497743 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
| US11013734 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
| US11376246 | RIGEL PHARMS INC | Inhibiting mutant IDH-1 |
May, 2039
(15 years from now) | |
| US11013733 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(15 years from now) | |
| US11738018 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(15 years from now) | |
| US11723905 | RIGEL PHARMS INC | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(15 years from now) | |
Rezlidhia is owned by Rigel Pharms Inc.
Rezlidhia contains Olutasidenib.
Rezlidhia has a total of 12 drug patents out of which 0 drug patents have expired.
Rezlidhia was authorised for market use on 01 December, 2022.
Rezlidhia is available in capsule;oral dosage forms.
Rezlidhia can be used as a method of treating an adult patient with relapsed or refractory acute myeloid leukemia having a susceptible idh1 mutation, a method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml), a method of treating a cancer where the cancer is acute myeloid leukemia (aml), a method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation.
Drug patent challenges can be filed against Rezlidhia from 01 December, 2026.
The generics of Rezlidhia are possible to be released after 12 November, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...
Dosage: CAPSULE;ORAL
REZLIDHIA family patents
